Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.53 |
| ▸ | BDNF | P23560 | 3/20 | 0.53 |
| ▸ | PTN | P21246 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | CCL2 | P13500 | 1/20 | 0.38 |
| ▸ | CCL5 | P13501 | 1/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | FGF2 | P09038 | 2/20 | 0.36 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531877 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL5790851 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL18079769 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL13321878 | 0.94 | MDK (0.61) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29371806 | 0.94 | MDK (0.61) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29501172 | 0.94 | BDNF (0.49) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29523446 | 0.94 | BDNF (0.49) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL23336378 | 0.91 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL23135897 | 0.89 | BDNF (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29362404 | 0.89 | MDK (0.44) | MDKBDNFPTNMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564661-B2 | Approach to repair tissue defects by bonding injectable gels to native soft tissues | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4130741-B1 | METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME | FUJIREBIO KK (JP) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025125099-A1 | HIGHLY SELECTIVE DIALYSIS MEMBRANES AND METHODS FOR PREPARING SAME | GAMBRO LUNDIA AB (SE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4570364-A1 | HIGHLY SELECTIVE DIALYSIS MEMBRANES AND METHODS FOR PREPARING SAME | Gambro Lundia AB (SE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025085478-A1 | METHODS FOR ANALYZING A PROCESSED NERVE GRAFT | AXOGEN CORPORATION (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250124576-A1 | METHODS FOR ANALYZING A PROCESSED NERVE GRAFT | AXOGEN CORPORATION | 2025-04-17 | — | — | US | disclosed |
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| CN-116083461-B | Recombinant pichia pastoris for producing medical leech hyaluronidase and construction method thereof | 江苏瑞霆生物科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230158210-A1 | IIMPROVED APPROACH TO REPAIR TISSUE DEFECTS BY BONDING INJECTABLE GELS TO NATIVE SOFT TISSUES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-05-25 | — | — | US | disclosed |
| US-20230160912-A1 | METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME | FUJIREBIO INC. (JP) | 2023-05-25 | — | — | US | disclosed |
| CN-116083461-A | Recombinant pichia pastoris for producing medical leech hyaluronidase and construction method thereof | 江苏瑞霆生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4130741-A1 | METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME | Fujirebio Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564661-B2 | Approach to repair tissue defects by bonding injectable gels to native soft tissues | UTRN, CD44, COL2A1 | MDK 450/4885BDNF 2483/4885PTN 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.